MediciNova, Inc.

Forte Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune diseases. Their lead product candidate, FB102, is a proprietary molecule with potentially broad applications in treating various autoimmune and autoimmune-related conditions. FB102 works by acting as a CD122 antagonist, which targets key pathways involved in the regulation of immune cells like NK cells and specific T cell subsets. The company successfully completed a Phase 1 clinical trial, demonstrating a positive safety profile and supporting the effectiveness of their approach.

Forte Biosciences is currently conducting patient-based studies for celiac disease, a condition that impacts millions of people worldwide. They are actively exploring the potential of FB102 for other autoimmune conditions such as vitiligo, Type 1 diabetes, and alopecia areata. The company is headquartered in Dallas, Texas, and is committed to developing safe and effective treatments that address the significant unmet needs of patients with autoimmune disorders.

Forte Biosciences is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoimmune diseases and related conditions. Their lead product candidate, FB102, is a proprietary molecule with potential broad applications across various autoimmune disorders. The company's mission is to address key pathways implicated in autoimmune diseases by utilizing CD122 antagonists, which are designed to modulate the activity of natural killer cells and certain T cell subsets, ultimately aiming to improve the lives of patients suffering from these debilitating conditions.